Fintech News

‹ Latest Events

NVAX
NASDAQ

Novavax, Inc.

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines - NVAX

Published October 12, 2026

$12.66
+0.00%
Event

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines - NVAX

Read full article on zacks.com →
About Novavax, Inc.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Stock Price
$11.26
Price Change
-1.56%
Exchange Mix — Recent NVAX Events

NASDAQ

100%

NYSE

0%

AMEX

0%

OTC

0%